First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials.
Schuler M, Paz-Ares L, Sequist LV, Hirsh V, Lee KH, Wu YL, Lu S, Zhou C, Feng J, Ellis SH, Samuelsen CH, Tang W, Märten A, Ehrnrooth E, Park K, Yang JC.
Schuler M, et al. Among authors: samuelsen ch.
Lung Cancer. 2019 Jul;133:10-19. doi: 10.1016/j.lungcan.2019.04.006. Epub 2019 Apr 8.
Lung Cancer. 2019.
PMID: 31200814
Free article.
Clinical Trial.